Short Interest in Trillium Therapeutics Inc (NASDAQ:TRIL) Expands By 425.8%

Share on StockTwits

Trillium Therapeutics Inc (NASDAQ:TRIL) (TSE:TR) was the target of a significant increase in short interest during the month of March. As of March 13th, there was short interest totalling 3,990,100 shares, an increase of 425.8% from the February 27th total of 758,900 shares. Based on an average daily trading volume, of 4,986,700 shares, the short-interest ratio is currently 0.8 days. Currently, 6.2% of the company’s stock are short sold.

Shares of NASDAQ TRIL opened at $3.95 on Friday. The business’s 50 day moving average price is $4.30 and its two-hundred day moving average price is $1.81. The company has a market cap of $327.00 million, a PE ratio of -2.82 and a beta of 2.28. Trillium Therapeutics has a twelve month low of $0.24 and a twelve month high of $7.97.

A hedge fund recently bought a new stake in Trillium Therapeutics stock. Jane Street Group LLC bought a new position in shares of Trillium Therapeutics Inc (NASDAQ:TRIL) (TSE:TR) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 28,588 shares of the biotechnology company’s stock, valued at approximately $29,000. Jane Street Group LLC owned 0.10% of Trillium Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 30.45% of the company’s stock.

Several analysts have issued reports on TRIL shares. Zacks Investment Research cut shares of Trillium Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, March 17th. ValuEngine downgraded shares of Trillium Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, March 13th. Finally, Cowen restated a “buy” rating on shares of Trillium Therapeutics in a research note on Tuesday, January 7th.

About Trillium Therapeutics

Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trials for advanced hematologic malignancies, and solid tumors and mycosis fungoides.

Featured Story: Understanding debt-to-equity ratio in fundamental analysis

Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Engrave Wealth Partners LLC Buys New Position in Vulcan Materials
Engrave Wealth Partners LLC Buys New Position in Vulcan Materials
Engrave Wealth Partners LLC Invests $26,000 in U.S. Bancorp
Engrave Wealth Partners LLC Invests $26,000 in U.S. Bancorp
DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main Trims Stock Holdings in J M Smucker Co
DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main Trims Stock Holdings in J M Smucker Co
Engrave Wealth Partners LLC Invests $28,000 in Hewlett Packard Enterprise Co
Engrave Wealth Partners LLC Invests $28,000 in Hewlett Packard Enterprise Co
DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main Sells 100,000 Shares of Silvercorp Metals Inc
DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main Sells 100,000 Shares of Silvercorp Metals Inc
DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main Boosts Holdings in Kirkland Lake Gold Ltd
DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main Boosts Holdings in Kirkland Lake Gold Ltd


© 2006-2020 Ticker Report